TickerFacts.

Insight Molecular Diagnostics Inc. (IMDX): Cost of Revenue

Annual figures by period end, from SEC filings.

$1.75M
Year ended 2025-12-31
+25.8%
3-year compound annual growth
-1.2%
5-year compound annual growth
$1.85M2020-12-31: $1.85M2021-12-31: $697.0K2022-12-31: $880.0K2023-12-31: $1.00M2024-12-31: $1.05M2025-12-31: $1.75M$1.75M
2020-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$1.75M+66.2%2026-03-26, From 2025-01-01
2024-12-31$1.05M+5.1%2026-03-26, From 2024-01-01
2023-12-31$1.00M+13.9%2025-03-24, From 2023-01-01
2022-12-31$880.0K+26.3%2024-04-16, From 2022-01-01
2021-12-31$697.0K-62.4%2023-04-12, From 2021-01-01
2020-12-31$1.85Mn/a2022-03-11, From 2020-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$1.75M+66.2%
Biomerica Inc (BMRA)2026-05-31$4.09M-15.0%
Anbio Biotechnology (NNNN)2025-12-31$1.10M-52.0%
Aspira Women's Health Inc. (AWHL)2025-12-31$3.30M-10.9%
Celldex Therapeutics, Inc. (CLDX)2025-12-31$200.0K0.0%
Immucell Corp (ICCC)2025-12-31$16.20M-12.7%
Alpha Teknova, Inc. (TKNO)2025-12-31$27.08M-11.3%
Myriad Genetics Inc (MYGN)2025-12-31$247.90M-1.7%
Neogen Corp (NEOG)2026-05-31$461.90M-2.4%

Compare IMDX, BMRA, NNNN, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗